| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
11,784 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,025 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
6,000,000 |
6,500,000 |
| Total Sell Value |
$0 |
$0 |
$3,000,000 |
$5,657,240 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2023-08-25 |
4 |
D |
$0.77 |
$792 |
D/D |
(1,029) |
137,300 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2023-08-25 |
4 |
D |
$0.77 |
$1,023 |
D/D |
(1,329) |
132,334 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2023-08-25 |
4 |
D |
$0.77 |
$1,482 |
D/D |
(1,925) |
214,396 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2023-08-25 |
4 |
D |
$0.77 |
$1,023 |
D/D |
(1,329) |
128,091 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-Chief Development Officer |
• – – |
2023-08-25 |
4 |
D |
$0.77 |
$1,126 |
D/D |
(1,462) |
140,634 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2023-08-13 |
4 |
D |
$1.08 |
$933 |
D/D |
(864) |
129,420 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2023-06-25 |
4 |
D |
$1.19 |
$13,718 |
D/D |
(11,528) |
211,321 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2023-06-11 |
4 |
D |
$1.19 |
$1,028 |
D/D |
(864) |
133,663 |
|
- |
|
| Carey Robert |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
49,600 |
|
- |
|
| Parker H Stewart |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
62,600 |
|
- |
|
| Smith Karen L. |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
52,100 |
|
- |
|
| Hillan Kenneth |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
49,600 |
|
- |
|
| Beers Courtney |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
32,650 |
|
- |
|
| Meyers James R |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
49,600 |
|
- |
|
| Horn Margaret A |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
32,650 |
|
- |
|
| Markels John |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,900 |
46,384 |
|
- |
|
| Mcclung David Mark |
EVP, Chief Operating Officer |
• – – |
2023-05-25 |
4 |
D |
$1.33 |
$2,560 |
D/D |
(1,925) |
222,849 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-Chief Development Officer |
• – – |
2023-05-25 |
4 |
D |
$1.33 |
$1,944 |
D/D |
(1,462) |
137,096 |
|
- |
|
| Macrae Sandy |
President, CEO and Director |
• • – |
2023-05-25 |
4 |
D |
$1.33 |
$13,847 |
D/D |
(10,411) |
613,298 |
|
- |
|
| Fontenot Jason D. |
SVP, Chief Scientific Officer |
• – – |
2023-05-25 |
4 |
D |
$1.33 |
$1,369 |
D/D |
(1,029) |
138,329 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2023-05-25 |
4 |
D |
$1.33 |
$1,766 |
D/D |
(1,328) |
125,284 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2023-05-25 |
4 |
D |
$1.33 |
$1,766 |
D/D |
(1,328) |
132,052 |
|
- |
|
| Ramelmeier Rolf Andrew |
EVP, Technical Operations |
• – – |
2023-05-25 |
4 |
D |
$1.33 |
$2,328 |
D/D |
(1,750) |
171,467 |
|
- |
|
| Willoughby Scott B. |
SVP, Gen. Counsel & Secretary |
• – – |
2023-04-24 |
4 |
D |
$1.65 |
$6,562 |
D/D |
(3,977) |
126,612 |
|
- |
|
| Duraibabu Prathyusha |
SVP, Chief Financial Officer |
• – – |
2023-03-25 |
4 |
D |
$1.66 |
$573 |
D/D |
(345) |
133,380 |
|
- |
|
1096 Records found
|
|
Page 2 of 44 |
|
|
0.04 (6.83%) 
